A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus.

Trial Profile

A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Insulin peglispro (Primary) ; Insulin; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Sep 2013 Results of an analysis in patients who underwent euglycaemic clamping (n=23) presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 05 Jul 2013 An Eli Lilly media release announces that an additional analysis exploring reduced mealtime insulin requirements for type 1 diabetes patients treated with insulin peglispro will be presented at the 73rd Annual ADA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top